drugset / Trial / NCT04733742

Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

NCT04733742

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this trial is to investigate whether intravenous rhTNK-tPA prior to endovascular treatment can improve 90-day functional outcome of stroke patients with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of symptom onset.

Timeline

Start
2022-05-09
Primary completion
2024-12-16
Completion
2025-02-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic Intravenous

Indications